Multidimensional Colloidal Nano Silver - SilverSol®: Can It Be a Repurposing Candidate for Cancer Treatment?

Background: Cancer remains the second leading cause of mortality worldwide, currently with 10 million annual deaths and projected prevalence of 32.6 million by 2045. Given the severe side effects of conventional treatments like chemotherapy and radiation, nanotechnology offers a promising new approach. Silver has a long-standing reputation in biomedicine. Nono silver has received significant attention as a potential therapeutic agent in various ailments including cancer. SilverSol®, a patented colloidal nano silver is a safe and potent multidimensional therapeutic agent. It is marketed for wound healing, vaginal infections, and various skin and oral-dental conditions over two decades. This vast clinical experience of its use prompted the present evaluation for its anticancer activity in vitro. We also further critically appraise its anticancer potential as a possible repurposing agent. Material and Method: Anticancer activity was tested in vitro and IC50 values were determined against ten cancer cell lines, covering seven cancer types. Results: Six of the ten cell lines exhibited higher sensitivity to SilverSol® (IC50 – 0.5 to 15.1 μg/ml) than the standard drugs. Four of these – Caco2 human colon adenocarcinoma cells, C6 glioblastoma, A549 lung adenocarcinoma, and the cervical cancers HeLa and SiHa – demonstrated IC50 values below 5 μg/ml. Conclusion: SilverSol® demonstrates significant anticancer potential in vitro. Salient features of SilverSol® and established multidimensional efficacy and remarkable safety profiles in several ailments, collectively provide a reasonable grounding for further exploration as a potential repurposing agent.